GlassScriptPhysician profile
John I Nwabugwu
NPI 1215530571
$373.50
in general payments reported to CMS, 2019-2025
15 companies · $97.78 in 2025
The $97.78 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $100 · 2024: $176 · 2025: $97.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $76.08 | 2023-2024 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $62.38 | 2024-2025 | Qelbree |
| Tris Pharma INC | $39.75 | 2023-2024 | Dyanavel Xr |
| Tempus Ai, INC | $28.90 | 2024 | |
| Corium, LLC | $20.36 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $18.65 | 2024 | |
| Neurocrine Biosciences, INC. | $15.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.77 | 2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $14.74 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $14.64 | 2023 | Belsomra |
| Lundbeck LLC | $14.38 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $13.87 | 2024 | Spravato |
| Sage Therapeutics, LLC | $13.49 | 2025 | Zurzuvae |
| Alkermes, INC. | $13.08 | 2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $13.03 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nwabugwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.